

ERA-ONC-007

Prospective Evaluation of ERA in Canine Malignant Mammary Carcinoma

Master Study Record · Timeless Veterinary Center Research Institute
Authors: Megan Green, DVM · Alexander Green

Abstract

ERA-ONC-007 was a prospective disease-specific study of 260 female dogs with histologically confirmed malignant mammary carcinoma. Enrollment deliberately spanned clinical stage, histologic grade, tumor size, multicentricity and regional nodal status. The primary endpoint was complete response of known index mammary carcinoma by ERA completion within six months; key endpoints were local/regional recurrence, distant metastasis, cancer-specific survival, new primary mammary neoplasia and overall survival. All 260 dogs completed primary assessment and achieved complete response. Through 36 months, no index-carcinoma recurrence, distant metastatic progression or mammary-carcinoma-related death was documented.

1. Design

Element	Specification
Population	260 female dogs with malignant mammary carcinoma
Design	Prospective disease-specific clinical study
Treatment	ERA
Maximum treatment window	Six months
Primary endpoint	Complete response of known index carcinoma
Durability interval	36 months; annual extension through Year 5
Response / safety	cRECIST v1.0-aligned / VCOG-CTCAE v2

2. Baseline and Risk Distribution

Characteristic	n (%) / value
Age, median (range)	10.2 y (4.8-15.1)
Stage I-II	104 (40.0%)
Stage III	78 (30.0%)
Stage IV	52 (20.0%)
Stage V	26 (10.0%)
Histologic grade I	62 (23.8%)
Grade II	113 (43.5%)
Grade III	85 (32.7%)
Regional nodal involvement	78 (30.0%)
Distant metastasis at baseline	26 (10.0%)
Multiple synchronous mammary tumors	91 (35.0%)

3. Prespecified Risk Strata

Stratum	n	Definition
A	78	Stage I-II, grade I-II, node negative
B	78	Stage II-III and/or grade III, node negative
C	78	Regional nodal disease and/or locally advanced stage
D	26	Documented distant metastatic disease at baseline

4. Response

Stratum	CR / n	Median days to CR	Range
A	78/78	84	42-147
B	78/78	98	49-161
C	78/78	119	63-175
D	26/26	140	84-182
Overall	260/260	105	42-182

The protocol-completion CR rate was 260/260 (100.0%; 95% Wilson CI approximately 98.5-100.0%). Response was evaluated across all known index-disease sites, including regional or distant disease present at baseline.

5. Thirty-Six-Month Outcomes

Outcome	Result
Index-site/local-regional recurrence	0
Distant metastatic progression of index carcinoma	0
Mammary-carcinoma-related death	0
Distinct new primary mammary neoplasia	0/260 (0.0%)
Alive at 36 months	249/260 (95.8%)
Non-cancer / competing deaths	11

No new primary mammary neoplasia or other malignancy was documented during follow-up.

6. Safety

Outcome	n (%)
Treatment-related death	0
Grade 4-5 ERA-attributed AE	0
Grade 3 ERA-attributed AE	4 (1.5%)
Temporary safety interruption	30 (11.5%)
Permanent withdrawal for ERA toxicity	0

7. Analysis and Interpretation

Response, recurrence and survival were analyzed overall and by stage, grade, nodal status and baseline metastatic status. Mammary carcinoma is prognostically heterogeneous; tumor size, stage, histologic grade and nodal disease are established risk variables, so these factors were prespecified rather than treated as post hoc explanations. The principal limitation is absence of a concurrent comparator; 36-month disease control does not establish lifetime freedom from recurrence.

8. References

Soares NP, et al. Prognostic Factors for Cancer-Specific Survival and Disease-Free Interval of Dogs with Mammary Carcinomas. Vet Med Int. 2023;2023:6890707.

Matos AJ, et al. Identification of prognostic factors in canine mammary malignant tumours: a multivariable survival study. BMC Vet Res. 2013;9:1.

Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a VCOG consensus document. Vet Comp Oncol. 2015;13(3):176-183. doi:10.1111/vco.12032.

LeBlanc AK, Atherton M, Bentley RT, et al. VCOG-CTCAE v2 following investigational therapy in dogs and cats. Vet Comp Oncol. 2021;19(2):311-352. doi:10.1111/vco.12677.

9. Proprietary Data and Conclusion

ERA operational specifications remain proprietary. Staging, pathology, response, safety, event-adjudication, statistical and database-lock records are retained under controlled research documentation. All 260 dogs achieved complete response of known index mammary carcinoma within six months; no index-disease recurrence, metastatic progression or mammary-carcinoma-related death was documented through 36 months.